Johnny Bullock, MD
Family Medicine · Foxworth, MSNPI 1043268709
Payments from drug & device makers
Across 211 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$867
- AstraZeneca$720
- AbbVie$280
- Novo Nordisk$273
- Lilly USA, LLC$154
- Axsome Therapeutics, Inc.$150
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,932100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $867 |
| AstraZeneca | 36 | $720 |
| AbbVie | 24 | $280 |
| Novo Nordisk | 18 | $273 |
| Lilly USA, LLC | 8 | $154 |
| Axsome Therapeutics, Inc. | 3 | $150 |
| Boehringer Ingelheim | 9 | $142 |
| Astellas Pharma US Inc | 7 | $138 |
| GSK | 8 | $128 |
| Exact Sciences | 6 | $122 |
| Amgen | 7 | $121 |
| Pfizer | 6 | $114 |
| Novartis | 6 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $108 |
| Merck | 4 | $104 |
| Baxter Healthcare | 2 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $56 |
| Viatris Specialty LLC | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Lundbeck LLC | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$113
How this compares
$3,932 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $194,792 |
| JardianceEmpagliflozin | 241 | $186,349 |
| MounjaroTirzepatide | 90 | $130,314 |
| EliquisApixaban | 107 | $91,182 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $87,269 |
| LinzessLinaclotide | 93 | $76,300 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $57,732 |
| XareltoRivaroxaban | 74 | $50,756 |
| TrulicityDulaglutide | 26 | $43,469 |
| EntrestoSacubitril/Valsartan | 46 | $39,707 |
| VraylarCariprazine Hcl | 19 | $33,505 |
| JanuviaSitagliptin Phosphate | 35 | $27,958 |
| GemtesaVibegron | 40 | $26,050 |
| FarxigaDapagliflozin Propanediol | 39 | $24,755 |
| MyrbetriqMirabegron | 45 | $23,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $142 | $196,387255 claims |
| Novo NordiskOzempic | $273 | $194,792174 claims |
| Lilly USA, LLCMounjaro, Trulicity | $154 | $173,783116 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $280 | $120,491123 claims |
| PfizerEliquis, Premarin | $114 | $96,087119 claims |
| GSKTrelegy Ellipta | $128 | $87,269110 claims |
| NovartisEntresto | $113 | $39,70746 claims |
| AstraZenecaFarxiga, Symbicort | $720 | $34,49969 claims |
| MerckJanuvia | $104 | $27,95835 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $56 | $26,05040 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $23,24645 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $20 | $9,87421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Foxworth
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.